KR102429704B1 - Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물 - Google Patents

Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물 Download PDF

Info

Publication number
KR102429704B1
KR102429704B1 KR1020217026744A KR20217026744A KR102429704B1 KR 102429704 B1 KR102429704 B1 KR 102429704B1 KR 1020217026744 A KR1020217026744 A KR 1020217026744A KR 20217026744 A KR20217026744 A KR 20217026744A KR 102429704 B1 KR102429704 B1 KR 102429704B1
Authority
KR
South Korea
Prior art keywords
compound
present disclosure
bcl
group
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217026744A
Other languages
English (en)
Korean (ko)
Other versions
KR20210107170A (ko
Inventor
샤오멩 왕
지안용 첸
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 미시건
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 미시건 filed Critical 더 리젠츠 오브 더 유니버시티 오브 미시건
Publication of KR20210107170A publication Critical patent/KR20210107170A/ko
Application granted granted Critical
Publication of KR102429704B1 publication Critical patent/KR102429704B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020217026744A 2016-08-05 2017-08-04 Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물 Active KR102429704B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662371504P 2016-08-05 2016-08-05
US62/371,504 2016-08-05
US201762454101P 2017-02-03 2017-02-03
US62/454,101 2017-02-03
PCT/US2017/045428 WO2018027097A1 (en) 2016-08-05 2017-08-04 N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
KR1020197002744A KR102376764B1 (ko) 2016-08-05 2017-08-04 Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197002744A Division KR102376764B1 (ko) 2016-08-05 2017-08-04 Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물

Publications (2)

Publication Number Publication Date
KR20210107170A KR20210107170A (ko) 2021-08-31
KR102429704B1 true KR102429704B1 (ko) 2022-08-04

Family

ID=59677319

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217026744A Active KR102429704B1 (ko) 2016-08-05 2017-08-04 Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물
KR1020197002744A Active KR102376764B1 (ko) 2016-08-05 2017-08-04 Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197002744A Active KR102376764B1 (ko) 2016-08-05 2017-08-04 Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물

Country Status (27)

Country Link
US (3) US10829488B2 (enExample)
EP (3) EP4129999A1 (enExample)
JP (2) JP6651180B2 (enExample)
KR (2) KR102429704B1 (enExample)
CN (2) CN110483501B (enExample)
AU (2) AU2017305508B2 (enExample)
CA (1) CA3031419C (enExample)
CY (1) CY1123859T1 (enExample)
DK (1) DK3494115T3 (enExample)
ES (1) ES2849959T3 (enExample)
HR (1) HRP20202073T1 (enExample)
HU (1) HUE053414T2 (enExample)
IL (2) IL264059B (enExample)
LT (1) LT3494115T (enExample)
MX (2) MX381588B (enExample)
MY (1) MY199409A (enExample)
PE (1) PE20190711A1 (enExample)
PH (1) PH12019500231A1 (enExample)
PT (1) PT3494115T (enExample)
RS (1) RS61821B1 (enExample)
RU (2) RU2722560C1 (enExample)
SA (1) SA519401020B1 (enExample)
SG (2) SG11201900135YA (enExample)
SI (1) SI3494115T1 (enExample)
SM (1) SMT202100025T1 (enExample)
WO (1) WO2018027097A1 (enExample)
ZA (2) ZA201900240B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11001582B2 (en) * 2016-03-10 2021-05-11 Assia Chemical Industries Ltd. Solid state forms of Venetoclax and processes for preparation of Venetoclax
MX381588B (es) * 2016-08-05 2025-03-12 Univ Michigan Regents N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
EP3565815B1 (en) 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
AU2018255621B2 (en) * 2017-04-18 2022-03-10 Fochon Pharmaceuticals, Ltd. Apoptosis-inducing agents
PL3788042T3 (pl) 2018-04-29 2025-06-02 Beigene Switzerland Gmbh Inhibitory bcl-2
CN114522167A (zh) * 2018-07-31 2022-05-24 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
CN110772639B (zh) * 2018-07-31 2021-04-13 苏州亚盛药业有限公司 Bcl-2抑制剂与MDM2抑制剂的组合产品及其在预防和/或治疗疾病中的用途
CA3095699A1 (en) * 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
AU2019315466B2 (en) * 2018-07-31 2022-05-19 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
EP3706741A4 (en) * 2018-11-23 2022-03-30 Ascentage Pharma (Suzhou) Co., Ltd. PHARMACEUTICAL COMPOSITION AND USE THEREOF
TWI770503B (zh) * 2019-05-13 2022-07-11 大陸商蘇州亞盛藥業有限公司 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物
CN112168830B (zh) * 2019-07-02 2022-01-25 苏州亚盛药业有限公司 一种含有mTOR抑制剂的药物组合及其应用
CN112294966B (zh) * 2019-07-31 2021-12-17 苏州亚盛药业有限公司 Bcl-2/Bcl-xL抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途
CN112852959A (zh) 2019-11-27 2021-05-28 苏州亚盛药业有限公司 用于预测靶向细胞凋亡途径的化合物的抗癌功效的方法和组合物
CN119097631A (zh) * 2019-12-03 2024-12-10 苏州亚盛药业有限公司 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物
CN112891353B (zh) * 2019-12-04 2024-01-30 苏州亚盛药业有限公司 药物组合及其用途
IL292882A (en) 2019-12-06 2022-07-01 Loxo Oncology Inc Dosage of Bruton's tyrosine kinase inhibitor
CN113354636B (zh) * 2020-03-06 2022-08-09 苏州亚盛药业有限公司 N-(苯基磺酰基)苯甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
WO2021180040A1 (zh) * 2020-03-12 2021-09-16 南京明德新药研发有限公司 苯并五元环类化合物
JP2023520843A (ja) 2020-04-15 2023-05-22 ベイジーン リミテッド Ｂｃｌ－２阻害剤
WO2021227763A1 (en) * 2020-05-14 2021-11-18 Ascentage Pharma (Suzhou) Co., Ltd. Hplc analysis method for n- (phenylsulfonyl) benzamide compound
WO2022002178A1 (en) * 2020-07-01 2022-01-06 Ascentage Pharma (Suzhou) Co., Ltd. Methods for synthesizing n-(phenylsulfonyl)benzamide compounds and intermediates thereof
CN111537654B (zh) * 2020-07-07 2020-11-10 上海亚盛医药科技有限公司 N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法
WO2022007940A1 (zh) * 2020-07-10 2022-01-13 江苏恒瑞医药股份有限公司 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用
CN114057728A (zh) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
CN114073707A (zh) * 2020-08-21 2022-02-22 苏州亚盛药业有限公司 治疗系统性红斑狼疮的组合物和方法
CN114073703B (zh) * 2020-08-21 2022-12-30 苏州亚盛药业有限公司 用于治疗非酒精性脂肪肝炎的组合物和方法
CN114533677A (zh) * 2020-11-25 2022-05-27 苏州亚盛药业有限公司 固体分散体、制剂、其制备方法及其应用
US20240316069A1 (en) * 2020-12-28 2024-09-26 Ascentage Pharma (Suzhou) Co., Ltd. Methods of treating multiple sclerosis
WO2022161496A1 (en) * 2021-02-01 2022-08-04 Ascentage Pharma (Suzhou) Co., Ltd. Sulfonyl benzamide derivatives as bcl-2 inhibitors
US20250319183A1 (en) 2021-04-07 2025-10-16 David Avigan Compositions and methods for the treatment of cancer
JP2024528174A (ja) 2021-08-02 2024-07-26 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド 医薬組合せおよびその使用
EP4442685A4 (en) * 2021-12-06 2025-11-19 Hangzhou Healzen Therapeutics Co Ltd BCL-2 PROTEIN ANTI-APOPTOTIC INHIBITOR: PHARMACEUTICAL COMPOSITION AND USES
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用
EP4421075A1 (en) * 2023-02-27 2024-08-28 KRKA, d.d., Novo mesto Process for the preparation of venetoclax and intermediates used therein
EP4676478A1 (en) 2023-03-03 2026-01-14 iOnctura SA Combination of roginolisib and bcl-2 inhibitor in the treatment of haematological malignancy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100305122A1 (en) 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021343A (en) 1912-01-17 1912-03-26 M A N Mfg Company Locking-clamp.
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
US7842681B2 (en) 2006-09-05 2010-11-30 Abbott Laboratories Treatment of myeoproliferative diseases
BRPI0719563A2 (pt) 2006-12-04 2013-12-10 Abbott Lab Ensaios diagnósticos amigáveis para terapia de câncer
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
TWI600642B (zh) 2008-12-05 2017-10-01 艾伯維有限公司 用於治療癌症及免疫疾病之ｂｃｌ-２-選擇性細胞凋亡誘發劑
CN104945311A (zh) 2009-01-19 2015-09-30 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CA2751293A1 (en) 2009-02-11 2010-08-19 Abbott Laboratories Methods and compositions for identifying, classifying and monitoring subject having bcl-2 family inhibitor-resistant tumors and cancers
AR076705A1 (es) * 2009-05-26 2011-06-29 Abbott Lab Agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
TWI520960B (zh) * 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
MX349533B (es) 2010-10-29 2017-08-02 Abbvie Inc Dispersiones solidas que contienen un agente inductor de apoptosis.
MY191300A (en) * 2010-11-23 2022-06-14 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
NZ610151A (en) * 2010-11-23 2015-06-26 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
US10362975B2 (en) 2015-12-30 2019-07-30 Dexcom, Inc. System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile and baseline model of sensors
MX381588B (es) * 2016-08-05 2025-03-12 Univ Michigan Regents N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100305122A1 (en) 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2013527202A (ja) 2010-05-26 2013-06-27 アッヴィ・インコーポレイテッド 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤

Also Published As

Publication number Publication date
US20190315739A1 (en) 2019-10-17
WO2018027097A1 (en) 2018-02-08
CN110483501B (zh) 2022-07-01
HUE053414T2 (hu) 2021-06-28
EP4129999A1 (en) 2023-02-08
KR20190035710A (ko) 2019-04-03
EP3494115A1 (en) 2019-06-12
KR20210107170A (ko) 2021-08-31
MX2020013014A (es) 2021-02-22
SG10201913643YA (en) 2020-03-30
RU2020114660A (ru) 2020-06-19
EP3494115B1 (en) 2020-10-21
MX2019001391A (es) 2019-06-06
HRP20202073T1 (hr) 2021-02-19
BR112019001666A2 (pt) 2019-05-28
LT3494115T (lt) 2021-01-25
RU2020114660A3 (enExample) 2020-09-15
RS61821B1 (sr) 2021-06-30
CN110483501A (zh) 2019-11-22
IL282099A (en) 2021-05-31
ZA201908466B (en) 2020-05-27
RU2722560C1 (ru) 2020-06-01
IL282099B (en) 2022-03-01
KR102376764B1 (ko) 2022-03-18
US20180354950A1 (en) 2018-12-13
SA519401020B1 (ar) 2022-03-16
CN109311871B (zh) 2020-02-28
US11718613B2 (en) 2023-08-08
ZA201900240B (en) 2020-05-27
SI3494115T1 (sl) 2021-02-26
AU2017305508B2 (en) 2021-01-07
DK3494115T3 (da) 2021-01-18
ES2849959T3 (es) 2021-08-24
RU2744358C2 (ru) 2021-03-05
US10221174B2 (en) 2019-03-05
CY1123859T1 (el) 2022-05-27
PE20190711A1 (es) 2019-05-17
IL264059B (en) 2021-05-31
JP2020007311A (ja) 2020-01-16
RU2020134802A (ru) 2022-04-25
AU2017305508A1 (en) 2019-02-07
EP3569601A2 (en) 2019-11-20
CA3031419C (en) 2021-08-24
JP2019527705A (ja) 2019-10-03
US10829488B2 (en) 2020-11-10
NZ750100A (en) 2021-01-29
AU2021202113A1 (en) 2021-05-06
PT3494115T (pt) 2021-01-15
PH12019500231A1 (en) 2019-07-29
MX381588B (es) 2025-03-12
EP3569601A3 (en) 2019-11-27
US20210002277A1 (en) 2021-01-07
CN109311871A (zh) 2019-02-05
CA3031419A1 (en) 2018-02-08
IL264059A (en) 2019-01-31
EP3569601B1 (en) 2022-06-22
SMT202100025T1 (it) 2021-03-15
JP6651180B2 (ja) 2020-02-19
MY199409A (en) 2023-10-25
JP7205903B2 (ja) 2023-01-17
SG11201900135YA (en) 2019-02-27
AU2021202113B2 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
KR102429704B1 (ko) Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물
EP4298098A1 (en) Sulfonyl benzamide derivatives as bcl-2 inhibitors
RU2831159C2 (ru) N-(фенилсульфонил) бензамиды и родственные соединения в качестве ингибиторов bcl-2
RU2831159C9 (ru) N-(фенилсульфонил) бензамиды и родственные соединения в качестве ингибиторов bcl-2
HK40001439B (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40001439A (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40019323B (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40019323A (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40001725B (en) N-(phenylsulfonyl)benzamide derivatives as bcl-2 inhibitors
HK40001725A (en) N-(phenylsulfonyl)benzamide derivatives as bcl-2 inhibitors
BR112019001666B1 (pt) Compostos de n-(fenilsulfonil)benzamidas e sais e solvatos dos mesmos, composições farmacêuticas e seus usos no tratamento de doenças, distúrbios ou afecções através da inibição de bcl-2
NZ750100B2 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4